Purpose: To validate the performance of a commercially-available, CE-certified deep learning (DL) system, RetCAD v.1.3.0 (Thirona, Nijmegen, The Netherlands), for the joint automatic detection of diabetic retinopathy (DR) and age-related macular degeneration (AMD) in color fundus (CF) images on a dataset with mixed presence of eye diseases.
Introduction
Screening for eye diseases has become a high-priority healthcare service to prevent vision loss. 1, 2 Due to its proven efficiency, screening programs based on periodical examinations of the retina have been increasingly implemented worldwide. [3] [4] [5] Established protocols rely on manual readings by highly-specialized workforce, 6 failing to meet the requirements of large-scale screening in high-and low-resource countries. [7] [8] [9] [10] [11] Furthermore, cost-effectiveness remains to be the main burden for establishing screening programs, 12-14 and different protocols are followed for different diseases, [15] [16] which translates to a larger burden to health systems and to the patient, that needs to undergo several of them. Nevertheless, exploiting the fact that examination protocols of retinal diseases rely mostly on the same principles and actions, it becomes more efficient to integrate them in one workflow.
17,18
Diabetic retinopathy (DR) has become a leading cause of preventable blindness worldwide with an overall prevalence of 35% among people with diabetes, which affects 1 in every 11 adults.
19-21 Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries, being 9% its worldwide prevalence. 22 Up to 80% of blindness cases caused by these diseases are avoidable if detected early enough to undergo treatment. 23, 24 Nevertheless, their incidence is expected to increase within the following decades, due to population ageing and the increasing prevalence of diabetes. 20, 22 Screening protocols for DR have been established in several countries. 25, 26 Regarding AMD, there is no established screening protocol but it will soon be required, 27,28 since treatment options are still limited, although under development.
29-30
Automated screening solutions aim to provide a scalable, sustainable and high-quality approach to meet the increasing demand, while reducing the burden on highly-trained professionals and the associated costs. The introduction of deep learning (DL) has constituted a revolution in medical imaging analysis. 32, 33 Previous solutions for the automatic analysis of retinal images 34, 35 have been outperformed by DL approaches. 36 Several DL systems for the automatic detection of DR [38] [39] [40] [41] and AMD 42-44 have showed performance close or even superior to that achieved by human graders. However, these systems perform independent analysis of each disease, although these diseases can co-exist and a solution for joint detection would be beneficial. 17, 18, 45 In this study, we present the validation of a commercially-available, CE-certified DL software package, RetCAD v.1.3.0 (Thirona, Nijmegen, The Netherlands), that allows for joint detection of referable DR and AMD in color fundus (CF) images. The aim is to analyze the capability of a DL system to simultaneously identify both diseases and compare it with human experts and the current state-of-the-art methods, in order to determine the potential for automated joint screening of eye diseases.
Methods

Evaluation data
The validation of the DL system was first performed on a DR-AMD dataset, which contains referable and non-referable cases of DR and AMD, for the joint detection of both diseases.
Additional validation of individual detection of DR and AMD was assessed on Messidor and the Age-Related Eye Disease Study (AREDS) dataset, respectively.
The DR-AMD dataset was extracted from a set of images collected in three different European medical centers (Sweden, Denmark, Spain). In total, 8871 images from more than 2000 patients were acquired during routine clinical practice between August 2011 and October 2016, with a CR-2PlusAF fundus camera (Canon, Tokyo, Japan), at 45-degree field of view with an image resolution between 2376×1584 and 5184×3456 pixels. No mydriasis was applied. Informed written consent was obtained from all patients at the medical centers and images were anonymized prior to transfer and use in this study, following the tenets set forth in the Declaration of Helsinki.
The 8871 images went through a human quality check, regarding contrast, clarity and focus, where 1785 images were excluded. The remaining 7086 images went through a preliminary grading, performed by a person with over six years of experience reading CF images. Images were classified as referable AMD (1232 images), referable DR (381 images) or control (5519 images), which indicates non-referability for both DR and AMD, although other diseases might be present. Lastly, a random selection of 600 images was performed, containing 150 referable AMD cases, 150 referable DR cases, and 300 controls, in order to ensure an enriched set. These images belong to 288 different patients, with an average of 2.11 images and 1.18 visits per patient.
The 600 images define the DR-AMD set used for validation of joint detection of DR and AMD.
The diagram in Supplementary Figure S1 summarizes the extraction of the dataset.
Messidor is a publicly-available collection of macula-centered CF images commonly used for performance comparison between automated DR detection systems. This dataset consists of 1200 images acquired by three different ophthalmologic departments using a 3CCD camera on a
Topcon TRC NW6 non-mydriatic retinography with a 45-degree field of view, with an image resolution of 1440×960, 2240×1488 or 2304×1536 pixels. 800 images were acquired with pupil dilation and 400 without dilation.
46
AREDS dataset is currently the largest available set for AMD, previously used for the validation of automated AMD detection. AREDS was designed as a long-term prospective study of AMD development and cataract in which patients were regularly examined and followed up to 12 years. 47 Institutional review board approvals were obtained from each clinical center involved in the study, and written informed consent was obtained from each participant. The AREDS dbGaP set includes digitalized CF images. In 2014, over 134,000 macula-centered CF images from 4613 participants were added to the set. We excluded images containing a lesion which disqualified an eye from the study, images considered as not gradable, and those which belong to eyes that were not included in the study, as mentioned in the AREDS dbGaP guidelines. 48 In total, 133821 were used in this study.
Grading
To establish the reference standard (RS) in the DR-AMD dataset, the 600 images were scored by stage of disease severity for both DR and AMD by a certified ophthalmologist with more than twelve years of experience (IC). In the case of DR, the grading is based on the International Clinical Diabetic Retinopathy (ICDR) severity scale, with stages 0 (no DR), 1 (mild nonproliferative DR), 2 (moderate non-proliferative DR), 3 (severe non-proliferative DR), and 4
(proliferative DR). 49 For AMD, the grading protocol is based on the AREDS system, with stages 1 (no AMD), 2 (early AMD), 3 (intermediate AMD), and 4 (advanced AMD; with presence of foveal geographic atrophy or choroidal neovascularization). 50 The measuring grid often used as part of the AREDS protocol was not applied for grading the DR-AMD dataset, taking into account lesions in the whole image and not only those located within the grid area.
For comparison with human performance at joint detection of DR and AMD, four independent observers also provided a score for each disease. Two of the graders were certified ophthalmologists with between one and three years of experience (VS, PH) and the other two graders were ophthalmology residents in their last year of residency (YL, AD).
The gradings from the RS and the independent observers were then adjusted for the adaptation of the detection of both diseases into two separate binary classifications. In the case of DR: non- The reference standard for the AREDS dataset corresponds to the publicly-available grading in AREDS dbGaP, which is based on the AREDS severity scale for AMD described previously.
48,50
These scores were assigned to the images by experts at US grading centers, being consistent with the original AREDS AMD categorization without considering visual acuity. 52 This RS was then adapted following the mentioned procedure into referable and non-referable cases for performing binary classification. Regarding validation of individual detection of referable DR and AMD, binary classification was performed between referable and non-referable DR cases in Messidor, and between referable and non-referable AMD cases in the AREDS dataset.
The performance metrics used for validation were sensitivity (SE) and specificity (SP), defined as the proportions of cases considered referable and non-referable, respectively, by both the system and the reference standard. The tradeoff between both metrics was furtherly observed by means of receiver operating characteristic (ROC) analysis. The optimal operating point of the system was considered to be the best tradeoff between SE and SP, i.e., the point closest to the upper left corner of the graph. For an overall interpretation of the system's ability to discriminate between referable and non-referable cases, the area under the ROC curve (AUC) was computed.
Human performance was also evaluated by computing sensitivity and specificity from the gradings of each observer and then included in the corresponding ROC curve as operating points.
Data bootstrapping was used to assess statistical significance of the obtained evaluation metrics.
58
Samples were bootstrapped 1000 times to generate a distribution of each evaluation metric, obtaining the 2.5 and 97.5 percentiles as 95% confidence intervals (CI).
Additionally, in the validation datasets where gradings by independent observers were available, i.e., DR-AMD dataset and Messidor, intergrader variability was measured by means of the quadratic Cohen's weighted kappa coefficient (κ), between gradings per disease stage and the corresponding reference standard.
59
Results
For the 600 images in the DR-AMD dataset, the ROC analysis corresponding to DR vs. AMD + controls is shown in Figure 1A . The optimal operating point of RetCAD v. Figure S2 and Supplementary Table S1 .
Intergrader disagreement in the DR-AMD dataset is shown in Figure 2 , which includes interrater heatmaps with quadratic-weighted κ scores among the four observers and the reference standard, for DR and AMD.
Regarding the performance validation of the system and external observers at detection of referable DR in Messidor, the obtained results can be found in Figure 3A . The AUC was 97.5%
(95% CI, 96.3%-98.5%), SE was 92.0% (95% CI, 89.3%-97.2%) and SP was 92.1% (95% CI, 88.6%-95.2%). Diagnostic performance by the system and the two observers is summarized in Supplementary Table S2 , while Supplementary Figure S3 shows the intergrader discrepancy among observers and the reference standard.
The results of the ROC analysis for automated detection of referable AMD in the AREDS dataset are shown in Figure 3B . 
Discussion
In this study we validated the performance for joint detection of referable DR and AMD of a commercially-available, CE-certified DL system, RetCAD v.1.3.0 (Thirona, Nijmegen, The Netherlands) and compared it with independent human observers. The results in the DR-AMD dataset show the system is able to differentiate between the two diseases, which is one of the main aspects in joint detection. When identifying referable DR, false positive detections can be divided in cases graded as control or referable AMD in the reference standard, being the latter the 17.4%
of the cases wrongly classified as referable DR. Regarding false positive cases at detection of referable AMD, 24.2% were graded as referable DR in the reference standard. Furthermore, the performance of the system is not significantly altered when individual disease detection is assessed on the same dataset.
The outcome of the joint validation also demonstrates the DL system performs comparably to human experts. RetCAD v.1.3.0 reaches lower specificity levels than human average, but higher sensitivity for both DR and AMD. This is particularly important at automated screening settings, where fewer referable cases must be missed when the system is used for either initial assessment or grading support. Figure S4 and Supplementary Table S4 ). This validation shows the capacity of a commercially-available DL system to assess joint detection of DR and AMD. However, future integration of automated detection of other eye diseases that might co-exist, such as glaucoma and cataracts, might increase usability and support at screening settings.
With respect to this study, the human observers were professional ophthalmologists or ophthalmologists in training, who are used to clinical working settings and tasks, where the prevalence of disease and manual grading tasks differ from those of real screening settings.
Besides, for evaluation of joint detection performance, one DR-AMD set of 600 images from 288 patients was used. In this dataset, patients might contain images from different visits, and in some cases, several images from the same visit. Future studies on automated joint screening would benefit from more and larger validation datasets, with more subjects and increased inter-subject variability, which would allow to analyse the effect of higher patient and imaging diversity on the performance of automated approaches. Additionally, these datasets would be even more beneficial by including graded cases with different severity levels for DR, AMD and additional eye diseases.
In conclusion, this validation study shows the capability of a commercially-available, CEcertified DL system to assess simultaneous detection of DR and AMD with performance comparable to human experts. This demonstrates that an automated solution for joint detection would be beneficial at screening settings, since eye diseases can co-exist and examination protocols rely on the same principles and actions, while reducing subjectivity due to interobserver disagreement. This also shows that DL systems can facilitate access to screening of eye diseases, both in high-and low-resource areas, and become a quick and reliable support for ophthalmological experts. Interrater heatmaps with quadratic Cohen's weighted kappa coefficients comparing disease staging for DR (A) and AMD (B) among the 4 independent human observers and the reference standard in the DR-AMD dataset (600 images with referable DR, AMD and control cases).
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The DR-AMD dataset was extracted from a set of 8871 images from more than 2000 patients collected in three different European medical centers (Sweden, Denmark, Spain) during routine clinical practice. Images went through a human quality check, regarding contrast, clarity and focus, where 1785 images were excluded. The remaining 7086 images went through a preliminary grading, performed by a person with over six years of experience reading CF images. Images were classified as referable AMD (1232 images), referable DR (381 images) or control (5519 images), which indicates non-referability for both DR and AMD, although other diseases might be present; 46 images were graded as having both referable AMD and DR present. Lastly, a random selection of 600 images was performed, containing 150 referable AMD cases, 150 referable DR cases, and 300 controls, in order to ensure an enriched set. These images belong to 288 different patients, with an average of 2.11 images and 1.18 visits per patient. The 600 images define the DR-AMD set used for validation of joint detection of DR and AMD. Figure S3 . Interrater disagreement in DR grading stages among independent human observers and reference standard in Messidor (1200 images). Figure S4 . Receiver operating characteristic curve for individual detection of referable DR in Messidor-2 (874 subjects).
